Altered coronary and cardiac adrenergic response in the failing hamster heart: Role of cyclooxygenase derivatives

Canadian Journal of Physiology and Pharmacology

Volumn 80, Issue 3, 2002, Pages 218-225

  Brousseau, Danica ^a   Desjardins, Jean François ^a   Jasmin, Gaëtan ^a   Dumont, Louis ^a  

^a UNIVERSITÉ DE MONTRÉAL   (Canada)

Author keywords

Adrenergic; Cardiac dynamics; Coronary flow; Cyclooxygenase; Heart failure

Indexed keywords

3 ISOPROPYLAMINO 1 (7 METHYL 4 INDANYLOXY) 2 BUTANOL; ALPHA 1 ADRENERGIC RECEPTOR BLOCKING AGENT; ALPHA 1 ADRENERGIC RECEPTOR STIMULATING AGENT; BETA 1 ADRENERGIC RECEPTOR BLOCKING AGENT; BETA 1 ADRENERGIC RECEPTOR STIMULATING AGENT; BETA 2 ADRENERGIC RECEPTOR BLOCKING AGENT; BETA 2 ADRENERGIC RECEPTOR STIMULATING AGENT; CYCLOOXYGENASE 2 INHIBITOR; DOBUTAMINE; INDOMETACIN; METOPROLOL; PRAZOSIN; PROSTAGLANDIN SYNTHASE; TERBUTALINE;

ADRENERGIC SYSTEM; ALPHA ADRENERGIC RECEPTOR BLOCKING; ALPHA ADRENERGIC STIMULATION; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; BETA ADRENERGIC RECEPTOR BLOCKING; BETA ADRENERGIC STIMULATION; CARDIOMYOPATHY; CONTROLLED STUDY; CORONARY ARTERY BLOOD FLOW; ENZYME ACTIVATION; ENZYME ACTIVITY; HAMSTER; HEART FAILURE; HEART FUNCTION; INOTROPISM; ISOLATED HEART; NONHUMAN; PRIORITY JOURNAL; VASODILATATION;

ADRENERGIC AGONISTS; ADRENERGIC ANTAGONISTS; ANIMALS; CORONARY CIRCULATION; CRICETINAE; CYCLOOXYGENASE INHIBITORS; DOBUTAMINE; HEART DISEASES; INDOMETHACIN; MESOCRICETUS; MYOCARDIAL CONTRACTION; PHENYLEPHRINE; RECEPTORS, ADRENERGIC, ALPHA-1; RECEPTORS, ADRENERGIC, BETA-1; RECEPTORS, ADRENERGIC, BETA-2; TERBUTALINE; VASODILATION;

EID: 0036211548     PISSN: 00084212     EISSN: None     Source Type: Journal    
DOI: 10.1139/y02-042     Document Type: Article

References (49)

1. 2-selective adrenoceptor antagonist (ICI118,551)
2. Increased responsiveness to stimulation of α- but not β-adrenoceptors in the hereditary cardiomyopathy of the Syrian hamster. Intact adenosine- and cholinoceptor-mediated isoprenaline antagonistic effect
3. 2-adrenergic receptor-mediated adenylate cyclase stimulation in nonfailing and failing human ventricular myocardium
4. β-adrenergic pathways in nonfailing and failing human ventricular myocardium
5. Adrenergic and muscarinic receptors in the human heart
6. Signal transduction mechanisms controlling cardiac contractility and their alterations in chronic heart failure
7. 31P MRS study
8. 2-adrenoceptor-mediated venoconstriction with indomethacin in humans
9. Evidence against significant resting sympathetic coronary vasoconstrictor tone in the conscious dog
10. Effects of prostacyclin on contractile properties of isolated mammalian cardiac muscle
11. Vascular alterations during the development and progression of experimental heart failure
12. Altered vascular function in early stages of heart failure in hamsters
13. Myocardial catecholamines and the patho-physiology of heart failure
14. Relevant features of the pharmacology of prazosin
15. Regulation of β-adrenoceptor signalling in cardiac function and disease
16. Microvascular spasm in the cardiomyopathic Syrian hamster: A preventable cause of focal myocardial necrosis
17. Effects of phosphoramidon, BQ 788, and BQ 123 on coronary and cardiac dysfunctions of the failing hamster heart
18. Possible involvement of free radicals and antioxidants in the early stages of the development of cardiomyopathy in BIO 14.6 Syrian hamster
19. Counteraction of the vasodilator effects of enalapril by aspirin in severe heart failure
20. 2+ stresses
21. Mechanisms of abnormal transmembrane signalling of the β-adrenergic receptor in congestive heart failure
22. Increased contractility in vascular smooth muscle of dystrophic hamsters
23. Hereditary polymyopathy and cardiomyopathy in the Syrian hamster. I. Progression of heart and skeletal muscle lesions in the UM-X7.1 line
24. Effects of atenolol, metoprolol, and pamatolol on cardiac and vascular beta-adrenoceptors in the rat
25. The sympathetic nervous system in chronic heart failure
26. Prostaglandin actions and interactions on isolated perfused rat hearts
27. β-adrenoceptor mediated signal transduction in congestive heart failure in cardiomyopathic (UM-X7.1) hamsters
28. Phospholipid metabolism in cardiomyopathic hamster heart cells
29. Prostacyclin increases cAMP in coronary arteries
30. α-adrenergic component of the sympathetic nervous system in congestive heart failure
31. Inhibitory role of the coronary arterial endothelium to α-adrenergic stimulation in experimental heart failure
32. Cellular and molecular aspects of contractile dysfunction in heart failure
33. Hypoxia-induced change in prostanoids production and coronary flow in isolated rat heart
34. Disruption of the dystrophin-glycoprotein complex in the cardiomyopathic hamster
35. Verapamil preserves myocardial contractility in the hereditary cardiomyopathy of the Syrian hamster
36. Alpha-1A adrenergic receptor stimulation with phenylephrine promotes arachidonic acid release by activation of phospholipase D in rat-1 fibroblasts: Inhibition by protein kinase A
37. 2+ sensitivity in enhanced vascular reactivity in cardiomyopathic hamsters
38. Adrenergic and muscarinic receptor regulation and therapeutic implications in heart failure
39. Hormones and hemodynamics in heart failure
40. Inotropic actions of eicosanoids
41. Norepinephrine turnover in the heart and spleen of the cardiomyopathic hamster
42. 2- adrenoceptor-mediated positive inotropic effects in human end-stage heart failure
43. Herditary and acquired cardiomyopathies in experimental animals: Mechanical, biochemical and structural features
44. 2-adrenoceptor to myocardial contraction in failing human myocardium
45. Impaired coronary sensitivity to diltiazem in heart failure: Involvement of the cyclooxygenase but not the nitric oxide-synthase pathway
46. Reactivity to endothelium-dependent and -independent vasoactive substances is maintained in coronary resistance vessels of the failing hamster heart
47. + adenosine triphosphate-dependent channels and cyclooxygenase activity
48. Alterations in protein kinase A and protein kinase C levels in heart failure due to genetic cardiomyopathy